Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Booster Vaccinations against Cancer Are Critical in Prophylactic but Detrimental in Therapeutic Settings
Alessia Ricupito, Matteo Grioni, Arianna Calcinotto, et al.
Cancer Research (2013) Vol. 73, Iss. 12, pp. 3545-3554
Open Access | Times Cited: 23

Showing 23 citing articles:

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
EA Mittendorf, Guy T. Clifton, Jarrod P. Holmes, et al.
Annals of Oncology (2014) Vol. 25, Iss. 9, pp. 1735-1742
Open Access | Times Cited: 221
Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy
Angela Rita Elia, Matteo Grioni, Veronica Basso, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 9, pp. 2171-2181
Open Access | Times Cited: 52
Induction of T-cell memory by a dendritic cell vaccine: a computational model
Francesco Pappalardo, Marzio Pennisi, Alessia Ricupito, et al.
Bioinformatics (2014) Vol. 30, Iss. 13, pp. 1884-1891
Open Access | Times Cited: 41
Dendritic cell regulation of NK‐cell responses involves lymphotoxin‐α, IL‐12, and TGF‐β
Dhifaf Sarhan, Marzia Palma, Yumeng Mao, et al.
European Journal of Immunology (2015) Vol. 45, Iss. 6, pp. 1783-1793
Open Access | Times Cited: 34
Prophylactic Dendritic Cell-Based Vaccines Efficiently Inhibit Metastases in Murine Metastatic Melanoma
Oleg V. Markov, Н. Л. Миронова, С. В. Сенников, et al.
PLoS ONE (2015) Vol. 10, Iss. 9, pp. e0136911-e0136911
Open Access | Times Cited: 29
The Dark Side of Dendritic Cells: Development and Exploitation of Tolerogenic Activity That Favor Tumor Outgrowth and Immune Escape
Barbara Seliger, Chiara Massa
Frontiers in Immunology (2013) Vol. 4
Open Access | Times Cited: 17
Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice
Romana Mikyšková, M Indrová, Ivan Štěpánek, et al.
OncoImmunology (2017) Vol. 6, Iss. 12, pp. e1362528-e1362528
Open Access | Times Cited: 16
Inefficacy of therapeutic cancer vaccines and proposed improvements. Casus of prostate cancer.
John J. L. Jacobs, Chantal Snackey, Albert A. Geldof, et al.
PubMed (2014) Vol. 34, Iss. 6, pp. 2689-700
Closed Access | Times Cited: 15
Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?
Maud Plantinga, Colin de Haar, Stefan Nierkens, et al.
Frontiers in Immunology (2014) Vol. 5
Open Access | Times Cited: 12
Efficacy of Dendritic Cell-Based Immunotherapy Produced from Cord Blood in vitro and in a Humanized NSG Mouse Cancer Model
Gang Liu, Fan Xiaoyan, Ying Cai, et al.
Immunotherapy (2019) Vol. 11, Iss. 7, pp. 599-616
Closed Access | Times Cited: 9
Molecular insights into the development of T cell-based immunotherapy for prostate cancer
Baijun Dong, Laurie J. Minze, Wei Xue, et al.
Expert Review of Clinical Immunology (2014) Vol. 10, Iss. 11, pp. 1547-1557
Closed Access | Times Cited: 8
Boosting anticancer vaccines
Alessia Ricupito, Matteo Grioni, Arianna Calcinotto, et al.
OncoImmunology (2013) Vol. 2, Iss. 7, pp. e25032-e25032
Open Access | Times Cited: 7
Immuno-kinetics of immunotherapy: dosing with DCs
Emek Köse, Sharon Moore, Chinenye Ofodile, et al.
Letters in Biomathematics (2017) Vol. 4, Iss. 1, pp. 39-58
Open Access | Times Cited: 6
Immuno-kinetics of Immunotherapy: Dosing with DCs
Emek Köse, Sharon Moore, Chinenye Ofodile, et al.
Letters in Biomathematics (2017) Vol. 4, Iss. 1
Open Access | Times Cited: 6
Adenovirus-Based Vectors for the Development of Prophylactic and Therapeutic Vaccines
Anton V. Borovjagin, Jorge G. Gómez-Gutiérrez, Haval Shirwan, et al.
(2014), pp. 203-271
Closed Access | Times Cited: 4
A Structured Population Model of Competition Between Cancer Cells and T Cells Under Immunotherapy
Marcello Delitala, Tommaso Lorenzi, Matteo Melensi
Springer proceedings in mathematics & statistics (2014), pp. 47-58
Closed Access | Times Cited: 4
Investigation of the Optimal Prime Boost Spacing Regimen for A Cancer Therapeutic Vaccine Targeting Human Papillomavirus
Diane M. Da Silva, Emma A. Martinez, Lies Bogaert, et al.
(2022)
Open Access | Times Cited: 3
Investigation of the Optimal Prime Boost Spacing Regimen for a Cancer Therapeutic Vaccine Targeting Human Papillomavirus
Diane M. Da Silva, Emma A. Martinez, Lies Bogaert, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4339-4339
Open Access | Times Cited: 3
Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response
John B. Liao, James Y. Dai, Jessica Reichow, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 11, pp. e010251-e010251
Open Access
The destiny of natural killer cells in the tumor microenvironment : to be suppressed or activated?
Dhifaf Sarhan
(2014)
Closed Access
Development of therapeutic vaccine strategies and pre-clinical animal tumor models for head and neck cancers
Rodney Macedo Gonzales
(2015)
Closed Access
Application of Antigen Cross-Presentation Research into Patient Care

Frontiers research topics (2017)
Open Access
Assessment of a novel mutated Prostatic Acid Phosphatase-derived vaccine for the treatment of prostate cancer
Pauline Le Vu
(2019)
Closed Access
Page 1

Scroll to top